Key result
Liposomal bupivacaine for perioperative fascia iliaca blockade during hip arthroscopy does not markedly decrease pain scores or opioid usage compared to plain bupivacaine.
Why the study?
Does liposomal bupivacaine decrease pain scores or opioid usage in patients undergoing hip arthroscopy compared to plain bupivacaine?
Does liposomal bupivacaine decrease pain scores or opioid usage in patients undergoing hip arthroscopy compared to plain bupivacaine?
Answers are grounded in this paper and cite their sources.
Liposomal bupivacaine does not provide significant advantages over plain bupivacaine for pain management in hip arthroscopy.
We read with great interest Purcell, Brooks, Steelman, Christensen, Dickens, Kent, McCabe, and Anderson’s recent study on “Fascia Iliaca Blockade With the Addition of Liposomal Bupivacaine Versus Plain Bupivacaine for Perioperative Pain Management During Hip Arthroscopy: A Double-Blinded Prospective Randomized Control Trial”1 and would like to congratulate the authors on conducting and publishing a well-designed nonpositive study. The results of the study suggest that the use of liposomal bupivacaine when performing a perioperative fascia iliaca peripheral nerve blockade (FICB) for patients undergoing hip arthroscopy does not markedly decrease pain scores or opioid usage in the perioperative period when compared to plain bupivacaine.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a letter in hip arthroscopy. Liposomal bupivacaine vs. Plain bupivacaine was evaluated on pain scores or opioid usage. Liposomal bupivacaine for perioperative fascia iliaca blockade during hip arthroscopy does not markedly decrease pain scores or opioid usage compared to plain bupivacaine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: